SiLaC Laser Technique for Pilonidal Sinus - La Paz Cohort Study.

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospital Universitario La Paz

About this trial

Pilonidal sinus disease (PSD) is a chronic inflammatory condition of the sacrococcygeal region that frequently affects young adults, often causing pain, drainage, and recurrent infection. Traditional surgical approaches such as wide excision or flap techniques may result in prolonged healing times, relevant postoperative pain, and recurrence rates up to 20-30%.

The SiLaC (Sinus Laser-Assisted Closure) technique is a minimally invasive procedure that uses a 1470-nm diode laser fiber to ablate the sinus epithelium and induce concentric contraction of the tract. International studies have reported promising results with faster recovery, minimal wound care, and low morbidity.

This prospective single-center cohort study aims to evaluate the clinical outcomes and perceived recovery time of adult patients treated with the SiLaC® technique at Hospital Universitario La Paz (Madrid, Spain). The main outcome is the total recovery time perceived by patients after surgery. Secondary outcomes include postoperative complications, recurrence rate, pain intensity, need for wound care, and patient satisfaction. Data will be collected from medical records and structured follow-up interviews.

Eligibility criteria

Qualifiers

Age ≥ 18 years.

Clinical diagnosis of chronic pilonidal sinus disease.

Undergoing surgery using the SiLaC (Sinus Laser-Assisted Closure) technique.

Signed informed consent for the use of anonymized clinical data for research purposes.

Disqualifiers

Patients with inflammatory bowel disease or complex anorectal fistulas.

Severe immunosuppression (active chemotherapy, high-intensity immunosuppressive therapy, uncontrolled HIV).

Prior pelvic radiotherapy.

Missing essential clinical data required for outcome assessment

Trial design

Treatments tested in this trial

  • SilaC

Treatment groups

40 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators